Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BEAUTIFUL
looks to me like some gorilla investors are positioning to get you what you are looking for.....we need power to overcome the evil ones
the turd will rise when the tide comes in
Pro traders will carry us home
Going to be a lot more from where that came from!
1 million shares good day coming
2018
448,000 at 1.72
429,000 shares at 1.66...looking good for the opening
Pre market stock is 1.81 up .46 or 34%
Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other Events
Item 8.01. Other Events.
In connection with the planned oral presentation of Heat Biologic’s Inc.’s (the “Company”) new HS-110 interim Phase 2 data at the upcoming 2019 ASCO-SITC Clinical Immuno-Oncology Symposium on February 28, 2019, by the principal investigator for the trial, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine, an abstract has been posted on the ASCO-SITC website.
The abstract summarizes interim data from the first two cohorts (A & B) of the Company’s Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer (NSCLC). Cohort A is comprised of previously-treated patients who have never received checkpoint inhibitor therapy; Cohort B is comprised of patients whose prior treatment does include checkpoint inhibitor therapy followed by disease progression.
Cohort A results are consistent with those reported in early 2018. With a median follow-up of 14.4 months in this cohort, the median overall survival has not yet been reached and 60% of patients remain alive. Protocol-defined subgroup analysis of patients categorized as ‘high’ or ‘low’ TIL (tumor infiltrating lymphocytes), based on levels of CD8+ cells present in the stroma of their tumor tissue at baseline, demonstrate a survival advantage for the ‘low TIL’ group as compared to the ‘high TIL’ group (not reached vs 13.8 months). Survival status was independent of patient PD-L1 expression levels on tumor samples from baseline. Objective Response Rate (ORR), Disease Control Rate (DCR) and Progression-Free Survival (PFS) per RECIST 1.1 are 18.6%, 48.8% and 1.9 months, respectively. The landmark 1 year PFS was 23.9% in Cohort A.
The abstract and presentation also contain the first data ever disclosed for Cohort B, patients whose disease progressed while receiving checkpoint inhibitor therapy at any time prior to study entry. Preliminary results suggest that adding HS-110 to nivolumab can restore responsiveness to checkpoint inhibitors with an investigator-assessed ORR of 22%, a DCR of 50%, and a median Progression-Free Survival of 2.2 months.
In both cohorts, combination with HS-110 and nivolumab was well-tolerated with the most common adverse events (AEs) reported as fatigue (31%), cough and diarrhea (19.7% each).
During the presentation, Dr. Morgensztern plans to discuss the interim results of the trial in greater detail along with a subset of correlative assessments and post-hoc analysis that support the mechanism of action of HS-110. Note that because the trial is still enrolling and new data has emerged since abstract submission in November 2018, Dr. Morgensztern’s presentation and poster will contain updated results which may vary from the original abstract. The complete abstract is available online at: abstracts.asco.org.
70 % of the world is covered in water and they can purify 99.9% of it......this year will be the year for a breakout....
https://www.sustainableresourcescorp.com/
I believe there is a lot of incognito activities going on with this company. And they are playing their cards close to their chest.
Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).
Bristol-Myers Squibb Company (BMS) is an American pharmaceutical company, headquartered in New York City.
Bristol-Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Could be Bristol-Myers Squibb-Heat one day.......stay tuned.....Bristol-Myers is running on the inside track.
There will be news this week....stock should start speculating upwards.
Get on board now, while it is cheap.
This stock/company is far from over!
This stock/company will be good to its shareholders. As the company gets more widely known, technology companies will be lining up to join their team. Looking forward to a future filled with cash.
This stock should start moving up this week. On Feb. 28 they are speaking at a Clinical-Immuno Oncological Symposium.
https://www.heatbio.com/news-media/news-releases/detail/621/heat-biologics-provides-clinical-and-business-update
This stock will surprise everyone!
Lack of current filings allows them to hide their program
They are forbidden to pump. We invest and let the market pros do the pump, we scope out stocks that are unavoidable, guaranteed pumps. Buying cheap over time is our specialty, before the investment community gets a whiff of what is going on. When everyone thinks this is the greatest thing since sliced bread, we exit and go on to the next guaranteed unavoidable pump.
They are forbidden to pump. We invest and let the market pros do the pump, we scope out stocks that are unavoidable, guaranteed pumps. Buying cheap over time is our specialty, before the investment community gets a whiff of what is going on. When everyone thinks this is the greatest thing since sliced bread, we exit and go on to the next guaranteed unavoidable pump.
No not a trick, just mega research. I have no intention of tricking people into buying stock, and for the record remember this is a .0001 stock it was already a POS before I came here. I'm just going to show you guys the light so that we can get out of it with a nice profit, just waiting till all my buds pick up shares. There is no rush folks, I think anyway. I would rather see everyone buy at .0001 than higher levels. Buy low sell high is a wonderful thing. The klowns at head office are good in tricking us, but I am better at reading their palms than they know. Remember you don't make money by buying and you don't make money by selling, you make it by waiting. GLTA
I have connected dots, that I will graciously share with you good people, absolutely nothing illegal about that.
I have some interesting information to share with everyone, but I am waiting till some shares are bought by my buddies before I put it out there. It involves this stock and others.....
Stock was dead already when we bought, but can easily be brought to life at will. There will be a pump, when is the million dollar question.
This stock was pumped on the opening of a twitter feed.......after the disappointment in the financial statements has been digested....they could set up a nice pump and dump play, so selling here is totally futile.......outsmart the klowns at head office
Well we will see what the klowns have been up to when the report comes out.
Well folks lets have a good day today. I just checked the twitter feed and no update. Not surprised, the klowns at head office still playing "hurry up and wait"
at this stage of the game there is nothing to worry about except "when"...........own enough where you can wait forever, but have enough so you can feel the joy of a pump........that way you can't lose
I am not too worried at this time.......its when the price jumps that I worry because I will want to get out without leaving any money on the table......the traders/pumpers need to make some coin as well so they will play this from this level....guaranteed.....just look at the twitter account and the pump they got from that "news"..........so you see my point they can pump a stock of this nature any time they please........when is the big guess
actually the glaciers are melting pretty fast,
yup looks like they are still dumping intermittently to give the appearance of being finished with dumping then they come in and whack a mole when our backs are turned
looks like the klowns at head office are trying to lure us into buying the triple zero ones by pulling them away then hitting us when our backs are turned
thumbs up to the trading.......I like the cleansing of the 0001s
that would be sweet
My guess is a news release tomorrow
...get out....at the perfect time....couple of investors have been calling IR but no luck........playing hide and seek till the news comes out.......I know it is cl*se........that is a bad word, that's why the asterisk
Still now twitter update, obviously the next tweet will be a done deal..........it is soooooooo obvious.........just keep adding .0001 when funds are available......its the only thing to do